Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06800729RecruitingPhase 1
Testing safety of TIX100 in healthy volunteers
This phase 1 study tests an experimental drug called TIX100 in healthy volunteers to check its safety and how the body processes it. The results will help determine if the drug can be studied in future trials for conditions like obesity or metabolic disorders.
Chula Vista, CaliforniaAges 18–70 - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07438106RecruitingPhase 2
HRS-4642 with chemo to shrink pancreatic cancer before surgery
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
NanjingAges 18–75 - NCT07444619RecruitingPhase 1
Combination drugs for returning soft tissue sarcoma in young people
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
Houston, TexasAges 1–30 - NCT07432022RecruitingPhase 1/Phase 2
EMB-07 combo for aggressive B-cell lymphoma
This trial tests a new combination treatment for people with aggressive B-cell non-Hodgkin lymphoma, including those with relapsed/refractory disease or newly diagnosed high-risk cases. It aims to see if EMB-07 combined with other drugs is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07432490RecruitingPhase 2
Fucose supplement trial for GLUT1 deficiency
This trial tests whether taking fucose (a type of sugar) can help people with GLUT1 deficiency syndrome, a rare genetic condition that affects how the brain gets energy. If you have ataxia (trouble with balance or coordination) and meet other criteria, this study may be an option for you.
Portland, OregonAges 18 years+ - NCT06733051RecruitingPhase 2
Study of Golidocitinib and Benmelstobart for relapsed ENKTL lymphoma
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07423000RecruitingPhase 1
Testing PVT401 in healthy volunteers
This study tests a new investigational drug called PVT401 in healthy people. It is a first-in-human study to see how the drug is handled by the body and to check for any side effects.
Melbourne, VictoriaAges 18–65 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Phoenix, ArizonaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07409428RecruitingPhase 3
Study of HMPL-760 plus R-GemOx for relapsed or refractory DLBCL
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07414602RecruitingPhase 1
Single dose study of SHR-1894 in healthy volunteers
This trial tests a single injection of a new medicine called SHR-1894 in healthy people to see how safe it is and how the body processes it. It helps find the right dose for future studies.
Chengdu, SichuanAges 18–45 - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT07405801RecruitingPhase 2
Inavolisib plus ribociclib plus fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Anaheim, CaliforniaAges 18 years+ - NCT07402369RecruitingPhase 2
Testing CMS-D002 for heavy bleeding from uterine fibroids
This trial tests a capsule called CMS-D002 for heavy periods caused by uterine fibroids. It might help reduce your bleeding if you have fibroids at least 2 cm in size, regular cycles, and are between 18 and 50.
Beijing, Beijing MunicipalityAges 18–50 - NCT07404865RecruitingPhase 3
Telitacicept for active primary Sjögren's disease
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Chandler, ArizonaAges 18–75 - NCT07402551RecruitingPhase 2
Testing RC1416 injection for COPD flare-ups
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
Hefei, AnhuiAges 40–85 - NCT07402512RecruitingPhase 3
Study of deuremidevir for RSV in infants and young children
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Xiamen, FujianAges 1 month–3 years - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT07392736RecruitingPhase 1/Phase 2
Study of AL8326 plus Toripalimab for advanced solid tumors
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT06631391RecruitingPhase 1
NK cell therapy for high-risk neuroblastoma in children
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
Guangzhou, GuangdongAges 1 day–18 years - NCT07382726RecruitingPhase 1
Study of izalontamab brengitecan plus adagrasib for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to a previous KRAS G12C inhibitor. The goal is to see if the combination is safe and works better than the single drug alone.
Houston, TexasAges 18 years+
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.